IMRT 2018

Remarks on IMRT for LA NSCLC

• IMRT is now standard for LA NSCLC radiotherapy • IMRT could reduce V20 and heart dose, reducing RP and possibly increasing survival • IMRT could increase patients’ compliance to chemotherapy • Ongoing trials will clarify us the role of PET-guided hypo- fractionated boost and the best chemotherapy combination (these trials are made possible by the use of IMRT!) • New drugs will hopefully amplify the benefit of the combined modality approach